Advancing Oncology Research with Molecular Affinity Analysis Technology

At Bavarian Biotech, we support academic researchers in oncology and drug development by offering services that use MAA (Molecular Affinity Analysis) for preclinical research and translational studies. MAA allows for in situ detection of therapeutically relevant regions and quantification of therapeutic binding site availability, supporting researchers working with preclinical models, patient derived xenografts, and novel drug candidates.

How MAA Can Support Your Research

Target Validation & Drug Development

  • Use MAA to detect therapeutically relevant regions and to quantify and visualize drug-target interactions in cell lines, patient-derived xenografts (PDX), and organoid models.
  • Compare MAA with conventional IHC to determine functional therapeutic target accessibility.

Preclinical Model Optimization

  • Evaluate how well your tumor models mimic human drug-target interactions using MAA.
  • Assess heterogeneity in target expression across different tumor models to select the most relevant system for drug testing.

Explore Tumor Heterogeneity 

  • Spatially visualize which tumor populations are engaged by your drug of interest.
  • Create a rationale for drug combination or therapy sequencing by exploring several drug target binding sites in the same slide using multiplexed MAA.

Predicting Drug Efficacy & Resistance Mechanisms

  • Investigate whether your drugs of interest effectively bind their targets on primary patient tissue to explore potential clinical benefits in diverse patient populations.
  • Identify potential mechanisms of drug resistance due to target downregulation or other therapy dynamic biomarkers.

Companion Biomarker Discovery

  • Use MAA-based profiling to identify potential predictive biomarkers for drug response in preclinical settings.
  • Validate biomarker expression across tumor models and primary tumor tissues to support clinical translation.
 

Our Services for Academic Researchers

Molecular Affinity Analysis (MAA) offers a wide range of applications for your preclinical and translational research projects.

Our services include:


  • MAA-Based Preclinical Tumor Profiling - Validate therapeutic target accessibility and

    binding site density in preclinical models or primary tumor samples.

  • Multiplexed approaches employing MAA alone and/or in combination with conventional biomarkers on the same tissue slide to investigate complex spatial distribution, co-expression and interaction. 
  • MAA-Based and conventional biomarker discovery on FFPE sections, frozen tissue, or other tissue types with the option to develop clinically meaningful companion diagnostics.

Partner with Us to Advance Precision Oncology

We invite you to connect with us to explore how our Molecular Affinity Analysis (MAA) platform can address your research and clinical objectives. Whether your focus is on enhancing clinical trial strategies, or advancing therapeutic profiling, our team is ready to provide tailored support and expert guidance.


Contact us to discuss your specific needs, request detailed information, or learn more about how MAA technology can contribute to your success in drug development and precision oncology.